B
Bin Fan
Researcher at Agios Pharmaceuticals
Publications - 51
Citations - 2980
Bin Fan is an academic researcher from Agios Pharmaceuticals. The author has contributed to research in topics: Isocitrate dehydrogenase & IDH1. The author has an hindex of 17, co-authored 40 publications receiving 1686 citations.
Papers
More filters
Journal ArticleDOI
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
Courtney D. DiNardo,Eytan M. Stein,S. de Botton,Gail J. Roboz,Jessica K. Altman,Alice S. Mims,Ronan T. Swords,Robert H. Collins,Gabriel N. Mannis,Daniel A. Pollyea,William B. Donnellan,Amir T. Fathi,A. Pigneux,Harry P. Erba,Gabrielle T. Prince,Anthony S. Stein,Geoffrey L. Uy,James M. Foran,Elie Traer,Robert K. Stuart,Martha Arellano,James L. Slack,Mikkael A. Sekeres,Christophe Willekens,Sung Choe,Hongfang Wang,Vickie Zhang,Katharine E. Yen,Stephanie M. Kapsalis,Hua Yang,David Dai,Bin Fan,Meredith Goldwasser,Hua Liu,Samuel V. Agresta,Bin Wu,Eyal C. Attar,Martin S. Tallman,Richard Stone,Hagop M. Kantarjian +39 more
TL;DR: In patients with advanced IDH1‐mutated relapsed or refractory AML, ivosidenib at a dose of 500 mg daily was associated with a low frequency of grade 3 or higher treatment‐related adverse events and with transfusion independence, durable remissions, and molecular remissions in some patients with complete remission.
Journal ArticleDOI
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
Ghassan K. Abou-Alfa,Ghassan K. Abou-Alfa,Teresa Macarulla,Milind Javle,Robin Kate Kelley,Sam J. Lubner,Jorge Adeva,James M. Cleary,Daniel V.T. Catenacci,Mitesh J. Borad,John Bridgewater,William P. Harris,Adrian Murphy,Do Youn Oh,Jonathan R. Whisenant,Maeve A. Lowery,Lipika Goyal,Rachna T. Shroff,Anthony B. El-Khoueiry,Bin Fan,Bin Wu,Christina X. Chamberlain,Liewen Jiang,Camelia Gliser,Shuchi Sumant Pandya,Juan W. Valle,Andrew X. Zhu,Andrew X. Zhu +27 more
TL;DR: Progression-free survival was significantly improved with ivosidenib compared with placebo, and ivOSidenib was well tolerated, and this study shows the clinical benefit of targeting IDH1 mutations in advanced,IDH1-mutant cholangiocarcinoma.
Journal ArticleDOI
Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia
Gail J. Roboz,Courtney D. DiNardo,Eytan M. Stein,Stéphane de Botton,Alice S. Mims,Gabrielle T. Prince,Jessica K. Altman,Martha Arellano,Will Donnellan,Harry P. Erba,Gabriel N. Mannis,Daniel A. Pollyea,Anthony S. Stein,Geoffrey L. Uy,Justin M. Watts,Amir T. Fathi,Hagop M. Kantarjian,Martin S. Tallman,Sung Choe,David Dai,Bin Fan,Hongfang Wang,Vickie Zhang,Katharine E. Yen,Stephanie M. Kapsalis,Denice Hickman,Hua Liu,Samuel V. Agresta,Bin Wu,Eyal C. Attar,Richard Stone +30 more
TL;DR: Ivosidenib monotherapy was well tolerated and induced durable remissions and transfusion independence in patients with newly diagnosed acute myeloid leukemia (AML).
Journal ArticleDOI
Ivosidenib in Isocitrate Dehydrogenase 1 - Mutated Advanced Glioma.
Ingo K. Mellinghoff,Benjamin M. Ellingson,Mehdi Touat,Elizabeth A. Maher,Macarena I. de la Fuente,Matthias Holdhoff,Gregory M. Cote,Howard A. Burris,Filip Janku,Robert J. Young,Raymond Y. Huang,Liewen Jiang,Sung Choe,Bin Fan,Katharine E. Yen,Min Lu,Chris Bowden,Lori Steelman,Shuchi Sumant Pandya,Timothy F. Cloughesy,Patrick Y. Wen +20 more
TL;DR: In patients with mIDH1 advanced glioma, ivosidenib 500 mg once per day was associated with a favorable safety profile, prolonged disease control, and reduced growth of nonenhancing tumors.
Journal ArticleDOI
Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study
Maeve A. Lowery,Howard A. Burris,Filip Janku,Rachna T. Shroff,James M. Cleary,Nilofer S. Azad,Lipika Goyal,Elizabeth A. Maher,Lia Gore,Antoine Hollebecque,Muralidhar Beeram,Jonathan C. Trent,Liewen Jiang,Bin Fan,Elia Aguado-Fraile,Sung Choe,Bin Wu,Camelia Gliser,Samuel V. Agresta,Shuchi Sumant Pandya,Andrew X. Zhu,Ghassan K. Abou-Alfa,Ghassan K. Abou-Alfa +22 more
TL;DR: Ivosidenib is an oral, targeted inhibitor of mutant IDH1 approved for the treatment of mIDH1 acute myeloid leukaemia in newly diagnosed patients ineligible for intensive chemotherapy and patients with relapsed or refractory disease.